APOA1 and breast cancer: In a placebo-controlled study involving 147 postmenopausal women with early breast cancer, exemestane had no major effect on the lipid profile except for a modest but significant decrease from baseline in HDL cholesterol (P < 0.001) and apolipoprotein A1 [42].